About this trial
The contribution of genetic risk factors to the development of focal dystonias is evident. However, understanding of how variations in the causative gene expression lead to variations in brain abnormalities in different phenotypes of dystonia (e.g., familial, sporadic) remains limited. The research program of the investigators is set to determine the relationship between brain changes and genetic risk factors in laryngeal dystonia (or spasmodic dysphonia). The researchers use a novel approach of combined imaging genetics, next-generation DNA sequencing, and clinical-behavioral testing. The use of a cross-disciplinary approach as a tool for the discovery of the mediating neural mechanisms that bridge the gap from DNA sequence to the pathophysiology of dystonia holds a promise for the understanding of the mechanistic aspects of brain function affected by risk gene variants, which can be used reliably for the discovery of associated genes and neural integrity markers for this disorder. The expected outcome of this study may lead to better clinical management of this disorder, including its improved detection, accurate diagnosis, and assessment of the risk of developing dystonia in family members.
Eligibility criteria
Qualifiers
Males and females of diverse racial and ethnic background, with age across the lifespan;
Laryngeal Dystonia patients
phenotype: adductor or abductor
genotype: familial or sporadic
Disqualifiers
Subjects who are incapable of giving informed consent.
Pregnant or breastfeeding women until a time when they are no longer pregnant or breastfeeding.
Subjects with past or present medical history of (a) major neurological problems, such as stroke, movement disorders (other than LD and VT in the patient groups), brain tumors, traumatic brain injury with loss of consciousness, ataxias, myopathies, myasthenia gravis, demyelinating diseases, alcoholism, drug dependence; (b) psychiatric problems, such as schizophrenia, bipolar depression, obsessive-compulsive disorder; (c) laryn¬geal problems, such as vocal fold paralysis, paresis, vocal fold nodules and polyps, carcinoma, chronic laryngitis.
Patients who are not symptomatic due to treatment with botulinum toxin injections into the laryngeal muscles.
Trial design
Treatments tested in this trial
- MRI
- Blood draw
Treatment groups
Sponsors and collaborators
Kristina Simonyan
Lead sponsor
Massachusetts Eye and Ear Infirmary
Sponsor institution
National Institute on Deafness and Other Communication Disorders (NIDCD)
Collaborator